Barton Shane 4
Research Summary
AI-generated summary
BioAge (BIOA) Principal Accounting Officer Barton Shane Exercises Options and Sells Shares
What Happened
Barton Shane, BioAge Labs' Principal Accounting Officer, exercised a total of 59,934 option shares (multiple grant tranches) on June 29–30, 2026, paying approximately $394,560 in exercise price. Nearly all resulting shares (and some previously held shares) were sold in open-market transactions: 42,350 shares on June 29 (weighted avg $25.21; proceeds $1,067,576) and 20,216 shares on June 30 (weighted avg $25.19; proceeds $509,176), for combined gross proceeds of about $1,576,752. The net effect of the reported activity is a reduction of 2,632 shares (sold 62,566 vs. acquired 59,934).
Key Details
- Transaction dates: June 29–30, 2026; Form 4 filed July 1, 2026 (appears timely).
- Options exercised by price tranches:
- 13,591 shares at $10.85 (cost $147,463)
- 11,261 shares at $8.39 (cost $94,480)
- 13,023 shares at $4.30 (cost $55,999)
- 22,059 shares at $4.38 (cost $96,618)
- Total exercised: 59,934 shares; total exercise cost: ~$394,560.
- Open-market sales:
- 42,350 shares on 6/29 — weighted avg $25.21 (prices ranged $25.00–$25.79) — proceeds $1,067,576.
- 20,216 shares on 6/30 — weighted avg $25.19 (prices ranged $25.00–$25.42) — proceeds $509,176.
- Total sold: 62,566 shares; total proceeds: ~$1.58M.
- The filing shows zero-dollar "disposed" entries for the option instruments (standard reporting when options convert to shares).
- Footnotes: transactions executed under a Rule 10b5-1 trading plan adopted Dec 16, 2025 (F1). Vesting schedules for the underlying options are described in footnotes F4–F7. F2/F3 note that sale prices are weighted averages across multiple executions; the filer will provide per-price breakdown on request.
- Shares owned after the transactions are not provided in the supplied data; based on these reported entries alone the net change is -2,632 shares.
Context
This was an exercise of vested options followed by open-market sales (consistent with a sell-to-cover or planned disposition). The sales were executed under a pre-established 10b5-1 plan, which typically schedules trades in advance and is intended to insulate the filer from trading on material nonpublic information. For retail investors: purchases (open-market buys) are usually more informative of bullish insider sentiment; here the activity is largely an option exercise and routine sale, not a straightforward buy signal.